SCYNEXIS, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
SCYNEXIS, Inc. (SCYX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 1.18% for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-29.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2021-03-29
- SCYNEXIS, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2020 was 1.18%, a 52.23% decline from fiscal 2019.
- SCYNEXIS, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2019 was 2.47%, a 6.44% decline from fiscal 2018.
- SCYNEXIS, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2018 was 2.64%, a 27.54% increase from fiscal 2017.
- SCYNEXIS, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2017 was 2.07%, a 39.86% increase from fiscal 2016.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|
| 2020-12-31 | 1.18% 10-K · filed 2021-03-29 |
| 2019-12-31 | 2.47% 10-K · filed 2021-03-29 |
| 2018-12-31 | 2.64% 10-K · filed 2020-03-11 |
| 2017-12-31 | 2.07% 10-K · filed 2019-03-14 |
| 2016-12-31 | 1.48% 10-K · filed 2018-03-13 |
| 2015-12-31 | 1.60% 10-K · filed 2017-03-13 |
| 2014-12-31 | 2.05% 10-K · filed 2017-03-13 |
| 2013-12-31 | 2.41% 8-K · filed 2015-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |